Danusertib binding and dissociation kinetics at Aurora A
Biochemical assay · Recombinant dephosphorylated human Aurora A kinase domain (residues 122–403); biotinylated T288V variant for surface-immobilized Creoptix WAVE measurements. [1]
Orthogonal binding measurements and global kinetic fitting support conformational selection followed by an induced-fit step. The fitted reverse conformational step differs from the observed slow-off rate; neither is a cellular IC50. Affinity estimates are assay-specific.
| Endpoint | Reported result | Reference |
|---|---|---|
| Equilibrium binding affinity to surface-immobilized Aurora A T288V | KD 1.1 ± 0.4 nM | [1] |
| Equilibrium binding affinity to solution-phase dephosphorylated Aurora A | KD 0.4 ± 0.1 nM | [1] |
| Observed slow dissociation after dilution of preformed Aurora A–danusertib complex | Observed off-rate (3.2 ± 0.3) × 10^-4 s^-1 | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- WAVE binding Methods: 0.13–66.67 nM danusertib; Figure 5G caption lists plotted series 0.1–64.8 nM. Fluorescence titration supplement: 0–11.25 nM. Slow-off assay: 30 nM Aurora A plus 30 nM danusertib before 30-fold dilution.
- Exposure duration
- Slow-off complex preincubated 1 h; fluorescence recorded every 160 s over 6 h. Equilibrium titration used 5 min equilibration after each addition.
- Method
- Binding/kinetic measurements at 25°C; stopped-flow traces averaged from replicate measurements and globally fitted with KinTek Explorer. WAVE reference channel and fluorimeter photobleaching control described in Methods.
- Vehicle
- DMSO drug stocks; stopped-flow buffer contained 5% DMSO. WAVE buffer formulation reported separately; final drug-derived DMSO fraction for danusertib WAVE binding not specified.
- Reported limits
- No cellular potency inferred. Figure-specific concentration series and Methods ranges are retained separately. The same-study solution and surface affinity estimates are not pooled; cause of their difference is not established.
Methods and source locations
Compound reported in the paper: Danusertib; Compound label in the paper: Danusertib (PHA739358)
Compound-level research evidence; the studies do not validate Adooq A10715, its lot, purity, salt form or stereochemistry. No salt or dose conversion applied.
Results: Kinetics of Danusertib binding to Aurora A; Figure 5B–I, Figure 6; Figure 5 supplements 1–2; Methods: stopped-flow, Creoptix WAVE, spectrofluorometer and macroscopic dissociation constant experiments
Equilibrium binding affinity to surface-immobilized Aurora A T288V: Creoptix WAVE waveguide interferometry at 25°C; equilibrium surface signal fitted against concentration. Figure 5 caption describes uncertainty as SD of fitted parameter. — Figure 5G–H and caption; Creoptix WAVE Methods
Equilibrium binding affinity to solution-phase dephosphorylated Aurora A: Tryptophan-fluorescence titration at 25°C; change at 368 nm fitted to Equation 6. Uncertainty is SD in fitted parameter per specific caption. — Figure 5—figure supplement 1D and caption; Macroscopic dissociation constant Methods
Observed slow dissociation after dilution of preformed Aurora A–danusertib complex: Fluorimeter at 25°C, 30-fold dilution after 1 h preincubation; single-exponential fit, with drug-free photobleaching control. Specific Figure 5 caption defines uncertainty as fitted-parameter SD. — Figure 5E and caption; Spectrofluorometer Methods